Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:IGXNASDAQ:PDPNASDAQ:PMNNASDAQ:RENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsPDPInvesco Dorsey Wright Momentum ETF$94.26+0.5%$95.51$72.68▼$99.60$1.22B1.0226,105 shs12,465 shsPMNProMIS Neurosciences$1.98+1.5%$2.04$0.95▼$8.95$37.54M0.6737,766 shs1,032 shsRENECartesian Growth Co. II$11.20-0.1%$11.11$10.52▼$11.92$242.14M-0.0162,779 shs16,141 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%PDPInvesco Dorsey Wright Momentum ETF+0.06%+1.91%-4.59%+7.89%+27.55%PMNProMIS Neurosciences0.00%-1.02%+0.52%-3.05%-71.28%RENECartesian Growth Co. II+0.09%+0.22%+0.90%+1.72%+6.56%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.9869 of 5 stars3.54.00.00.03.21.70.6RENECartesian Growth Co. IIN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXIntelGenx TechnologiesN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETF0.00N/A$97.303.23% UpsidePMNProMIS Neurosciences3.00Buy$8.00304.04% UpsideRENECartesian Growth Co. IIN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences$10K3,754.08N/AN/A$0.20 per share9.90RENECartesian Growth Co. IIN/AN/A$0.40 per share28.14($0.64) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETFN/AN/A25.46∞N/AN/AN/AN/AN/APMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)RENECartesian Growth Co. II$11.44MN/A0.00∞N/AN/A-65.59%5.02%N/ALatest RENE, PMN, PDP, and IGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXIntelGenx TechnologiesN/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETF$0.250.27%N/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/ALatest RENE, PMN, PDP, and IGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/15/2024PDPInvesco Dorsey Wright Momentum ETFQuarterly$0.02753/18/20243/19/20243/22/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXIntelGenx Technologies164.622.772.69PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/APMNProMIS NeurosciencesN/A1.461.46RENECartesian Growth Co. IIN/A0.220.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXIntelGenx TechnologiesN/APDPInvesco Dorsey Wright Momentum ETFN/APMNProMIS Neurosciences50.13%RENECartesian Growth Co. II58.96%Insider OwnershipCompanyInsider OwnershipIGXIntelGenx TechnologiesN/APDPInvesco Dorsey Wright Momentum ETFN/APMNProMIS Neurosciences10.30%RENECartesian Growth Co. II20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionablePDPInvesco Dorsey Wright Momentum ETFN/A12.89 millionN/AOptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableRENECartesian Growth Co. IIN/A21.62 million17.30 millionNot OptionableRENE, PMN, PDP, and IGX HeadlinesSourceHeadlineShort Interest in Cartesian Growth Co. II (NASDAQ:RENE) Increases By 312.5%marketbeat.com - April 25 at 10:22 PMWolverine Asset Management LLC Acquires 104,768 Shares of Cartesian Growth Co. II (NASDAQ:RENE)marketbeat.com - April 23 at 8:48 PMCartesian Growth Co. II (NASDAQ:RENE) Shares Up 0%americanbankingnews.com - April 19 at 2:58 AMCartesian Growth Co. II (NASDAQ:RENE) Short Interest Updatemarketbeat.com - March 28 at 8:23 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Invesco Dorsey Wright Momentum ETFNASDAQ:PDPPowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index includes approximately 100 the United States-listed companies. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Cartesian Growth Co. IINASDAQ:RENECartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.